MOONLAKE IMMUNOTHERAPEUTICS Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $279.36 thousand for the 10-month period ending 2021-12-31, per its 10-K filed 2023-03-20.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2023-03-20
- 2021-12-31: Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 10 month $279.36K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 10 month |
|---|---|
| 2021-12-31 | $279.36K 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |